These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 87982)

  • 21. Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.
    Green JA; Dawson AA; Fell LF; Murray S
    Br J Clin Pharmacol; 1980 May; 9(5):511-4. PubMed ID: 6893156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combined cyclic treatment of generalized Hodgkin's disease by the MOPP program. Preliminary results and observed complications].
    Mazurowa A; Krykowski E; Pluzańska A; Dmochowska M; Robak T; Polkowska-Kulesza E; Skorek TO; Fajndt S; Boguszewska E
    Pol Tyg Lek; 1977 Apr; 32(14):521-3. PubMed ID: 854465
    [No Abstract]   [Full Text] [Related]  

  • 23. [Alternating chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP); etoposide, procarbazine, vindesine and prednisolone (EPVP) as a treatment for advanced-stage Hodgkin's disease].
    Kumagai K; Takagi T; Sakai C; Wakatsuki S
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):499-501. PubMed ID: 8678506
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of dose and rate of administration of MOPP drugs in 97 retrospective Hodgkin's patients.
    Gobbi PG; Cavalli C; Rossi A; Bertoloni D; Galeone F; Pieresca C; Grignani E
    Haematologica; 1987; 72(6):523-8. PubMed ID: 3126109
    [No Abstract]   [Full Text] [Related]  

  • 25. Stage I and II Hodgkin's disease: involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP.
    Hagemeister FB; Fuller LM; Velasquez WS; Sullivan JA; North L; Butler JJ; Johnston DA; Shullenberger CC
    Cancer Treat Rep; 1982 Apr; 66(4):789-98. PubMed ID: 7074649
    [No Abstract]   [Full Text] [Related]  

  • 26. Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?
    Dodwell DJ; de Campos ES; Radford JA
    Drugs; 1992 Jul; 44(1):1-8. PubMed ID: 1379906
    [No Abstract]   [Full Text] [Related]  

  • 27. Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) chemotherapy.
    Diehl LF; Perry DJ; Terebelo H; Baldwin PE; Hurwitz M; Kimball DB; Dorn RV
    Cancer Treat Rep; 1983 Sep; 67(9):827-9. PubMed ID: 6883360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis of Hodgkin's disease: patients who fail to remit or who relapse after combination chemotherapy.
    Sutcliffe SB; Economopoulos T; Wrigley PF; Stansfeld AG; Malpas JS
    Clin Oncol; 1980 Dec; 6(4):329-36. PubMed ID: 6161731
    [No Abstract]   [Full Text] [Related]  

  • 29. [Combination chemotherapy of advanced Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
    Mizunuma N; Ogawa M; Kuraishi Y; Horikoshi N; Inoue K; Mukaiyama T; Fukutani H; Tabata M; Hirano A; Itami S
    Rinsho Ketsueki; 1991 Nov; 32(11):1410-5. PubMed ID: 1758048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Letter: Chemotherapy of Hodgkin's disease.
    Winokur SH
    N Engl J Med; 1974 Dec; 291(24):1309. PubMed ID: 4431438
    [No Abstract]   [Full Text] [Related]  

  • 32. [Chemotherapy-selective nodal irradiation in Hodgkin's disease clinical stages IA-IIIB. Results of a prospective clinical trial including 334 patients (author's transl)].
    Andrieu JM; Asselain B; Bayle C; Teillet F; Clot P; Dana M; Katz M; Brière J; Jacquillat C; Bernard J
    Bull Cancer; 1981; 68(2):190-9. PubMed ID: 7016225
    [No Abstract]   [Full Text] [Related]  

  • 33. Combination chemotherapy and survival in advanced Hodgkin's disease.
    Canellos GP; Young RC; Berard CW; DeVita VT
    Arch Intern Med; 1973 Mar; 131(3):388-90. PubMed ID: 4569375
    [No Abstract]   [Full Text] [Related]  

  • 34. Maternal and foetal outcome following Hodgkin's disease in pregnancy.
    Lishner M; Zemlickis D; Degendorfer P; Panzarella T; Sutcliffe SB; Koren G
    Br J Cancer; 1992 Jan; 65(1):114-7. PubMed ID: 1733434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hodgkin's lymphoma in children: results of treatment with the MOPP protocol and a combination of radiotherapy and chemotherapy].
    Vuković I; Janković MB; Janić D; Stojimirović E
    Srp Arh Celok Lek; 1985; 113(11-12):1013-21. PubMed ID: 3841764
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of Hodgkin's disease. Experience of the Hôpital Saint-Louis].
    Boiron M; Teillet F; Weisgerber C; Dana M; Jacquillat C; Bernard J
    Rev Prat; 1974 Oct; 24(45):3971-8. PubMed ID: 4445767
    [No Abstract]   [Full Text] [Related]  

  • 37. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
    Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
    J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hodgkin's disease in children; treatment results with or without radiotherapy].
    Behrendt H
    Ned Tijdschr Geneeskd; 1986 May; 130(19):865-8. PubMed ID: 3754935
    [No Abstract]   [Full Text] [Related]  

  • 39. MOPP, ABVD, or both to treat Hodgkin's disease.
    Martino R; Nomdedeu J; Brunet S
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680766
    [No Abstract]   [Full Text] [Related]  

  • 40. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.